Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.34 USD
Change Today +0.019 / 5.94%
Volume 1.5M
ETRM On Other Exchanges
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

enteromedics inc (ETRM) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/14/15 - $2.05
52 Week Low
07/22/15 - $0.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ENTEROMEDICS INC (ETRM)

enteromedics inc (ETRM) Related Businessweek News

No Related Businessweek News Found

enteromedics inc (ETRM) Details

EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company’s proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. It develops the Maestro Rechargeable System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. The company is evaluating the Maestro System in human clinical trials in the United States, Australia, and Mexico. It has collaboration with Mayo Clinic for the development and testing of products for the treatment of obesity. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.

28 Employees
Last Reported Date: 03/13/15
Founded in 2002

enteromedics inc (ETRM) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $410.2K
Co-Founder and Vice President of Clinical & R...
Total Annual Compensation: $297.2K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $338.3K
Senior Vice President of Research and Advance...
Total Annual Compensation: $296.6K
Compensation as of Fiscal Year 2014.

enteromedics inc (ETRM) Key Developments

EnteroMedics Announces Publication of 18 Month ReCharge Clinical Study Data in the Journal of Obesity

EnteroMedics Inc. announced that 18 month results from the Company's ReCharge Clinical Study were published in the Journal of Obesity, Volume 2015. The article, titled "Sustained Weight Loss with Vagal Nerve Blockade but Not with Sham: 18-Month Results of the ReCharge Trial," which highlights sustained weight loss in patients receiving vBloc® Neurometabolic Therapy, is available online here. The ReCharge Pivotal Trial is a randomized, double-blind, sham-controlled, multicenter pivotal clinical trial of vBloc® Neurometabolic Therapy in 239 patients with obesity. As described in the published data, at 12 months, patients in the vBloc Therapy group (n=162) demonstrated excess weight loss (EWL) of 25.8%, compared to 16.9% EWL in the Sham control group (N=77). At 18 months, the gap between the vBloc Therapy Group and the Sham group widened, with the vBloc Therapy group sustaining their weight loss at 23.5% EWL, compared to a significant excess weight regain in the Sham control group which had dropped to 10.2% EWL at the same time point. Sensitivity analyses showed that the unblinding of the trial did not significantly influence the larger treatment effect with vBloc over time, as most of the patients in the Sham group were still blinded at 16 months (P=0.34 for the unblinding by treatment interaction). Similarly, when the analysis was restricted to patients who remained blinded throughout 18 months, the estimated mean percent EWLs were similar to that of the overall sample. The safety profile of vBloc Therapy remained favorable at 18 months.

EnteroMedics Announces First US Commercial Implant of vBloc® Neurometabolic Therapy System at Tufts Medical Center in Boston, Massachusetts

EnteroMedics Inc. announced the first ever commercial implant of the Maestro® Rechargeable System, delivering vBloc® Neurometabolic Therapy, in the United States. The procedure was performed on May 13, 2015 at Tufts Medical Center by surgeon Sajani Shah, MD. The surgery proceeded without incident and the patient returned home on the same day as the surgery, is recovering well and has returned to work full-time. vBloc Therapy intermittently blocks intra-abdominal vagus nerve signaling, or transmission of messages involving food intake and processing, between the brain and stomach using a pacemaker-like implant called the Maestro® Rechargeable System. In January of this year, the system was approved for adults with a BMI of 40 to 45 kg/m2 or a BMI of 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years.

EnteroMedics Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

EnteroMedics Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported operating loss of $6.964 million against $6.558 million a year ago. Net loss was $7.174 million or $0.10 per diluted share against $6.732 million or $0.10 per diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ETRM:US $0.34 USD +0.019

ETRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ETRM.
View Industry Companies

Industry Analysis


Industry Average

Valuation ETRM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENTEROMEDICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at